It is unclear whether FLT3 overexpression alone would confer response to FLT3 inhibitors in KMT2A-r ALL or is merely a consequence of other genomic events and thus not essential for leukemia cell survival. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.